CancerScreen Panels

Highly optimized NGS panel for somatic cancer

Overview

CancerScreen Panel core/50/100/400

CancerScreen panel is an NGS assay designed to detect all types of variants for up to 407 genes associated with somatic cancer. Targeting the selected genes with high sensitivity and specificity enables saving cost and effort.

Celemics provides full exclusive bioinformatics support. The generated report consists of the primary, secondary, and tertiary results for the in-depth understanding and interpretation of sequencing data.

Also, if the gene of interest does not exist in the panel, it can be added separately through our gene add-on service

CancerScreen Panels
Features & Benefits

Optimized Comprehensive Panel for Solid Cancer Analysis

The panel is designed to assess the whole CDS region (RefSeq) of up to 407 genes and rearrangement regions associated with solid cancer. Using the CancerScreen panel, you can detect all mutation types, including SNV, Indel, Large Inde, CNV, rearrangements, MSI, and TMB in a single assay.

Performance Comparison with Competitor Product

  • Higher on-target ratio, uniformity, coverage at 100X compared to competitor product over the target regions including exons and introns
Performance Comparison with Competitor Product

Superior Sensitivity and Specificity

CancerScreen panel is suitable for detecting low-frequency and rare variants with high sequencing depths. With Celemics’ proprietary probe design technology, it provides superior capture performance even in GC-rich and homologous regions or any type of clinical samples, such as poor-quality FFPE or ctDNA with the highest sensitivity and specificity.

Maximized Sequencing Efficiency

Celemics’ assay and reagent optimization technology will significantly increase the sequencing efficiency while maintaining the market leading on-target ratio and uniformity. Also, the precisely optimized and balanced chemistry will allow panels and kits to be compatible with various sequencing platform of your choice at much reduced sequencing cost compared to other competitor products. 

Performance Comparison over GC-rich Regions

  • More uniform read depths over GC-rich regions compared to competitor products.
Performance Comparison over GC-rich Regions
Performance Comparison over GC-rich Regions

Specification

Gene count* 13/54/99/407 genes
Target size 61/197/299/1,123 kb + Rearrangement
Mutation type SNV, Indel, CNV, Rearrangement, MSI, TMB
Sample type(amount) FFPE, frozen tissue, cfDNA, RNA
Platform All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore
Bioinformatics Support ① Primary Analysis: FASTQ to annotated VCF
② Secondary Analysis: CNV, Large InDel
③ Tertiary Analysis: Clinical interpretation

Specification - Gene List

  • 13 genes | Gene count
  • 61 kb | Target Size
  • Whole CDS, Rearrangement | Target Region
ALK APC BRAF EGFR ERBB2 KRAS MET NRAS PIK3CA RET ROS1 SMAD4 TP53
  • 54 genes | Gene count
  • 197 kb | Target Size
  • Whole CDS, Rearrangement | Target Region
ABL1 AKT1 ALK APC ATM BRAF BRCA1 BRCA2 CDH1 CDK4 CDK6 CDKN2A
CSF1R CTNNB1 DDR2 EGFR ERBB2 ERBB4 ESR1 FGFR1 FGFR2 FGFR3 GNA11 GNAQ
GNAS HRAS IDH1 IDH2 JAK2 KDR KIT KRAS MAP2K1 MET MLH1 MTOR
MYC MYCN NOTCH1 NRAS NTRK1 PDGFRA PIK3CA PTCH1 PTEN PTPN11 RB1 RET
ROS1 SMAD4 SMO SRC STK11 TP53
  • 99 genes | Gene count
  • 299 kb | Target Size
  • CDS | Target Region
ABL1 AKT1 AKT2 AKT3 ALK APC ARID1A ARID1B ARID2 ATM ATRX AURKA
AURKB BARD1 BCL2 BLM BMPR1A BRAF BRCA1 BRCA2 BRIP1 CDH1 CDK4 CDK6
CDKN2A CHEK2 CSF1R CTNNB1 DDR2 EGFR EPCAM EPHB4 ERBB2 ERBB3 ERBB4 EZH2
FBXW7 FGFR1 FGFR2 FGFR3 FLT3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 IDH2
IGF1R ITK JAK1 JAK2 JAK3 KDR KIT KRAS MDM2 MET MLH1 MPL
MRE11 MSH2 MSH6 MTOR MUTYH NBN NF1 NOTCH1 NPM1 NRAS NTRK1 PALB2
PDGFRA PDGFRB PIK3CA PIK3R1 PMS2 PRSS1 PTCH1 PTCH2 PTEN PTPN11 RAD50 RAD51C
RAD51D RB1 RET ROS1 SLX4 SMAD4 SMARCB1 SMO SRC STK11 SYK TERT
TOP1 TP53 VHL
  • 407 genes | Gene count
  • 1,123 kb | Target Size
  • CDS | Target Region
ABL1 ABL2 ADGRA2 AKT1 AKT2 AKT3 ALK AMER1 APC APCDD1 APEX1 APOB
APOBEC1 AR ARAF ARFRP1 ARID1A ARID1B ARID2 ASXL1 ATM ATP11B ATR ATRX
AURKA AURKB AXIN1 AXL B2M B3GAT1 BACH1 BAP1 BARD1 BCL2 BCL6 BCL9
BCOR BCR BIRC2 BIRC3 BLM BRAF BRCA1 BRCA2 BRD2 BRD3 BRD4 BRIP1
BTG1 BTK BTLA CARD11 CASP5 CASP8 CBFB CBL CDK12 CDK4 CDK6 CDK8
CDKN1A CDKN1B CDKN2A CDKN2B CDKN2C CDX2 CEBPA CHD1 CHD2 CHD4 CHEK1 CHEK2
CHUK CIC CRBN CREBBP CRKL CRLF2 CSF1R CSF2 CSF2RA CSF2RB CSNK2A1 CTCF
CTLA4 CTNNA1 CTNNB1 CUL3 CUL4A CUL4B CXCL10 CXCL11 CXCL9 CXCR3 CYLD CYP17A1
DAXX DCUN1D1 DDR2 DICER1 DIS3 DNMT1 DNMT3A DOCK2 DOT1L EGFR ELMO1 EML4
EMSY EP300 EPHA3 EPHA5 EPHA6 EPHA7 EPHB1 EPHB4 EPHB6 ERBB2 ERBB3 ERBB4
ERCC1 ERCC2 ERG ERRFI1 ESR1 ETV1 ETV4 ETV5 ETV6 EWSR1 EYA2 EZH2
FANCA FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FAS FAT1 FAT3
FBXW7 FGF1 FGF10 FGF12 FGF14 FGF19 FGF2 FGF23 FGF3 FGF4 FGF6 FGF7
FGFR1 FGFR2 FGFR3 FGFR4 FH FLCN FLT1 FLT3 FLT4 FOXA1 FOXL2 FOXO3
FOXP3 FRS2 FUBP1 GABRA6 GAS6 GATA1 GATA2 GATA3 GATA4 GATA6 GID4 GLI1
GNA11 GNA13 GNAQ GNAS GRIN2A GRM3 GSK3B GUCY1A2 GZMA GZMB GZMH H3F3A
HGF HIST1H3B HNF1A HOXA3 HRAS HSD3B1 HSP90AA1 IDH1 IDH2 IDO1 IDO2 IFITM1
IFITM3 IFNA1 IFNB1 IFNG IGF1 IGF1R IGF2 IGF2R IKBKE IKZF1 IL12A IL12B
IL2 IL23A IL6 IL7R INHBA INPP4B INSR IRF2 IRF4 IRS2 ITGAE ITK
JAK1 JAK2 JAK3 JUN KAT6A KDM5A KDM5C KDM6A KDR KEAP1 KEL KIT
KLF4 KLHL6 KMT2A KMT2B KMT2C KNSTRN KRAS LAG3 LMO1 LRP1B LRP6 LTK
LYN LZTR1 MAGI2 MAGOH MAML1 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MAP3K13 MAPK1 MAX
MCL1 MDM2 MDM4 MED12 MEF2B MEN1 MET MITF MLH1 MPL MRE11 MSH2
MSH6 MTOR MUTYH MYB MYC MYCL MYCN MYD88 MYO18A NCOA3 NCOR1 NF1
NF2 NFE2L2 NFKBIA NOTCH1 NOTCH2 NOTCH3 NOTCH4 NPM1 NRAS NSD1 NSD3 NTRK1
NTRK2 NTRK3 NUP93 NUTM1 PAK3 PAK5 PALB2 PARP1 PARP2 PARP3 PARP4 PAX5
PBRM1 PDCD1 PDCD1LG2 PDGFRA PDGFRB PDK1 PGR PHF6 PHLPP2 PIK3C2B PIK3C3 PIK3CA
PIK3CB PIK3CG PIK3R2 PKHD1 PLCG1 PLCG2 PMS2 PNP PNRC1 POLD1 POLE PPARG
PPP2R1A PRDM1 PREX2 PRF1 PRKAR1A PRKCI PRKDC PRPF40B PRSS8 PTCH1 PTCH2 PTEN
PTK2 PTPN11 PTPRC PTPRD QKI RAB35 RAC1 RAC2 RAD17 RAD50 RAD51 RAD52
RAD54L RAF1 RANBP2 RARA RB1 RBM10 REL RET RHEB RHOA RHOB RICTOR
ROBO1 ROBO2 ROS1 RPA1 RPS6KB1 RPTOR RUNX1 RUNX1T1 RUNX3 SDHA SDHB SDHC
SDHD SEMA3A SEMA3E SET SETBP1 SETD2 SF3A1 SF3B1 SH2B3 SKP2 SLIT2 SMAD2
SMAD3 SMAD4 SRSF2 SRSF7 STAG2 STAT3 STAT4 TERT TET2

Related Products

Ready-to-use-panel

Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes

Ready-to-use-panel

Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer

Ready-to-use-panel

Covers all major genes, including coding exons, concerning mutation for FDA approved therapies

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Resources

Technical Resources

[Product Overview] CancerScreen Panel

[Product Overview] Celemics Target Enrichment Panel Overview

[Catalogue] Celemics Products & Service Catalogue_All Products & Service

Safety Data Sheets

MSDS_CancerScreen Panels_Illumina_Enzymeplus

MSDS_CancerScreen Panels_Illumina

MSDS_CancerScreen Panels_Thermo Fisher

MSDS_CancerScreen Panels_MGI_EnzymePlus

MSDS_CancerScreen Panels_MGI

References

Epigenomics

Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel

Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.

 

10.2217/epi-2021-0477


View Detail >

Investig Clin Urol

Germline pathogenic variants in unselected Korean men with prostate cancer

So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.

 

DOI 10.4111/icu.20220044


View Detail >

Scientific Reports

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.

 

DOI 10.1038/s41598-022-05931-3


View Detail >

BMC Medical Genomics

A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report

Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.

 

DOI 10.1186/s12920-022-01191-2


View Detail >